Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Effect of Chlorpromazine (Largactil®), a Dopamine Receptor Antagonist, on Esophageal Sensitivity in Healthy Volunteers: a Randomized, Double-blind, Placebo-controlled Study.

NCT03183310 is registered in ClinicalTrials.gov with Universitaire Ziekenhuizen KU Leuven as lead sponsor.

NCT NCT03183310
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03183310 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Effect of Chlorpromazine (Largactil®), a Dopamine Receptor Antagonist, on Esophageal Sensitivity in Healthy Volunteers: a Randomized, Double-blind, Placebo-controlled Study.
Lead sponsor
Universitaire Ziekenhuizen KU Leuven
Phase
Not applicable
Overall status
Unknown status
Start date
July 1, 2017
Completion date
October 31, 2017
Enrollment
14 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

esophageal reflux